Frequency of Myocardial Infarction and Comparison of Streptokinase Therapy Success Rate Based on Gender and Diabetes Status

Streptokinase Therapy Success in STEMI Patients

Authors

  • Muhammad Irfan Cardiovascular Technologist (Cath Lab), Peshawar Institute of Cardiology, Peshawar, Pakistan
  • Atta ul Wadood Postgraduate Resident, Adult Cardiology, Peshawar Institute of Cardiology, Peshawar, Pakistan
  • Sajjad Ur Rahman Postgraduate Resident, Adult Cardiology, Peshawar Institute of Cardiology, Peshawar, Pakistan
  • Ejaz Ali Khan Senior Nursing Lecturer, Khyber Pakhtunkhwa Institute of Medical Sciences, Peshawar, Pakistan
  • Shahab Afridi Ayub Medical College, Abbottabad, Pakistan

DOI:

https://doi.org/10.61919/jhrr.v4i3.1394

Keywords:

Myocardial Infarction, Streptokinase Therapy, Gender Differences, Diabetes Status, Treatment Outcomes

Abstract

Background: Acute ST-elevation myocardial infarction (STEMI) is a major cause of morbidity and mortality. Streptokinase is a widely used thrombolytic agent, but its efficacy may vary based on diabetic status and gender.
Objective: To compare the success rate of streptokinase therapy in STEMI patients based on diabetic status and gender.
Methods: A prospective cohort study was conducted in the Emergency Department of MTI Lady Reading Hospital, Peshawar, involving 310 STEMI patients treated with streptokinase. Patients were grouped by diabetic status (diabetic: 208; non-diabetic: 102) and gender (male: 183; female: 127). The success of therapy was defined as ≥70% ST-segment resolution on an ECG taken 90 minutes post-therapy. Data were analyzed using SPSS version 25 with Chi-square tests for categorical variables.
Results: Streptokinase success rates were higher in non-diabetic patients (76.5%) compared to diabetic patients (49.5%). Male patients showed a higher success rate (74.9%) than females (66.1%). Among non-diabetics, males had the highest success rate (92.9%), while diabetic females had the lowest (40.4%).
Conclusion: Streptokinase is more effective in non-diabetic and male STEMI patients. Gender and diabetic status should guide therapy decisions.

Downloads

Download data is not yet available.

References

K Sembulingam P, Sembulingam. Medical Physiology. 6th ed. Jaypee brothers Medical Publishers; 1113 p.

Hall JE. Textbook of Medical Physiology. 13th ed. 1046 p.

Snell RS. Clinical Anatomy. 9th ed.

Innes JA. Essentials of Medicine. 2nd ed. ELSEVIER;

Shah I, Hafizullah M, Shah S, Gul A, Iqbal A. Comparison of the Efficacy and Safety of Thrombolytic Therapy for St-Elevation Myocardial Infarction in Patients With and Without Diabetes Mellitus. Pakistan Hear J. 2012;45(1):33–8.

Chowdhury MAR, Hossain AKMM, Dey SR, Akhtaruzzaman AKM, Islam N-A-F. A comparative study on the effect of streptokinase between diabetic and non-diabetic myocardial infarction patients. Bangladesh J Pharmacol. 2008;3(1):1–7.

Gill BUA, Ramzan M, Ahmed N, Abbas T, Qureshi BA, Saleemi MS, et al. Efficacy of Streptokinase in Diabetic and Non-Diabetic Patients Presenting With Acute St Elevation. Pakistan Hear J. 2014;47(02):96–9.

Hasan A, Tawab S, Arif M, Muzamil M, Javed A, Aslam M. Effect of Gender on Efficacy of Streptokinase in Acute St Segment Elevation Myocardial Infarction. Pakistan Hear J. 2019;52(3):254–7.

Schroder R. Intravenous short-term infusion of streptokinase in acute myocardial infarction. Texas Hear Inst J. 1984;11(1):18–23.

Brown BG, Gallery CA, Badger RS, Kennedy JW, Mathey D, Bolson EL, et al. Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: Quantitative angiographic observations. Circulation. 1986;73(4):653–61.

Neuhaus KL, Tebbe U, Sauer G, Kreuzer H, Köstering H. High dose intravenous streptokinase in acute myocardial infarction. Clin Cardiol. 1983;6(9):426–34.

Hillis LD, Borer J, Braunwald E, Chesebro JH, Cohen LS, Dalen J, et al. High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multicenter trial. J Am Coll Cardiol [Internet]. 1985;6(5):957–62. Available from: http://dx.doi.org/10.1016/S0735-1097(85)80294-1

Chew E, Morton P, Murtagh JG, Scott ME, Keeffe DBO. late potentials. 1990;5:5–8.

Rentrop KP, Blanke H, Karsch KR, Wiegand V, Köstering H, Oster H, et al. Acute myocardial infarction: Intracoronary application of nitroglycerin and streptokinase. Clin Cardiol. 1979;2(5):354–63.

Goldhammer E, Kharash L, Abinader EG. Circadian fluctuations in the efficacy of thrombolysis with streptokinase. Postgrad Med J. 1999;75(889):667–71.

Bock PE, Fuentes-Prior P. Streptokinase. Toxins Hemost From Bench to Bedside. 2011;163(1949):429–44.

Crawford MH. Current Diagnosis and Treatment Cardiology, Fifth Edition.

Chatterjee K, Topol EJ. Cardiac Drugs.

Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology, 9 Edition.

Downloads

Published

2024-09-01

How to Cite

Irfan , M., Atta ul Wadood, Sajjad Ur Rahman, Ejaz Ali Khan, & Shahab Afridi. (2024). Frequency of Myocardial Infarction and Comparison of Streptokinase Therapy Success Rate Based on Gender and Diabetes Status: Streptokinase Therapy Success in STEMI Patients. Journal of Health and Rehabilitation Research, 4(3), 1–4. https://doi.org/10.61919/jhrr.v4i3.1394